cilostazol has been researched along with Abdominal Migraine in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale)." | 9.27 | Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. ( Falkenberg, K; Olesen, J, 2018) |
| "Whether migraine headache and migraine aura share common pathophysiological mechanisms remains to be understood." | 6.87 | Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. ( Butt, JH; Hansen, AS; Kruuse, C; Lambertsen, KL; Rostrup, E, 2018) |
| "Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale)." | 5.27 | Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. ( Falkenberg, K; Olesen, J, 2018) |
| "Our study revealed that migraine attacks can be provoked in patients by cAMP-mediated mechanisms using cilostazol, even when the CGRP receptor is blocked by erenumab." | 3.30 | Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans. ( Al-Karagholi, MA; Amirguliyev, S; Ashina, M; Deligianni, C; Do, TP; Guo, S; Lopez, CL; Snellman, J, 2023) |
| "Thirty patients with migraine without aura received 200 mg cilostazol on two different study days." | 2.94 | Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. ( Bjerg, HR; Falkenberg, K; Olesen, J, 2020) |
| "The origin of migraine pain is unknown but possibly implicates the dura mater, which is pain sensitive in proximity to the meningeal arteries." | 2.90 | Meningeal contribution to migraine pain: a magnetic resonance angiography study. ( Amin, FM; Ashina, M; Christensen, CE; de Koning, PJH; Ghanizada, H; Khan, S; Larsson, HBW; Olinger, ACR; Younis, S, 2019) |
| "Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist." | 2.90 | Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. ( Amin, FM; Ashina, M; Birgens, H; Christensen, CE; Daldrup-Link, H; Fliedner, FP; Khan, S; Kjær, A; Larsson, HBW; Lindberg, U; Olinger, ACR; Tolnai, D; Younis, S, 2019) |
| "Only subjects who developed migraine-like attacks on study day 1 were included on study day 2." | 2.87 | Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. ( Amin, FM; Ashina, M; Deen, M; Hougaard, A; Khan, S, 2018) |
| "Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP." | 2.87 | Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. ( Ashina, M; Dunga, BÓÁ; Falkenberg, K; Guo, S; Olesen, J, 2018) |
| "Whether migraine headache and migraine aura share common pathophysiological mechanisms remains to be understood." | 2.87 | Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. ( Butt, JH; Hansen, AS; Kruuse, C; Lambertsen, KL; Rostrup, E, 2018) |
| "A model for the testing of novel antimigraine drugs should ideally use healthy volunteers for ease of recruiting." | 2.82 | Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. ( Ashina, M; Guo, S; Hansen, EK; Olesen, J, 2016) |
| "Various substances are known to trigger migraine attacks in patients and calcitonin gene-related peptide antagonising drugs are effective against migraine pain." | 1.62 | CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine. ( Chaker, J; Christensen, SL; Christensen, ST; David, A; Ernstsen, C; Haanes, KA; Kristensen, DM; La Cour, S; Olesen, J; Rasmussen, RH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Do, TP | 1 |
| Deligianni, C | 1 |
| Amirguliyev, S | 1 |
| Snellman, J | 1 |
| Lopez, CL | 1 |
| Al-Karagholi, MA | 1 |
| Guo, S | 3 |
| Ashina, M | 6 |
| Falkenberg, K | 3 |
| Bjerg, HR | 1 |
| Olesen, J | 6 |
| Christensen, SL | 2 |
| Rasmussen, RH | 1 |
| Ernstsen, C | 1 |
| La Cour, S | 1 |
| David, A | 1 |
| Chaker, J | 1 |
| Haanes, KA | 1 |
| Christensen, ST | 1 |
| Kristensen, DM | 1 |
| Khan, S | 3 |
| Deen, M | 1 |
| Hougaard, A | 1 |
| Amin, FM | 3 |
| Petersen, S | 1 |
| Sørensen, DB | 1 |
| Jansen-Olesen, I | 1 |
| Holland, PR | 1 |
| Strother, L | 1 |
| Dunga, BÓÁ | 1 |
| Butt, JH | 1 |
| Rostrup, E | 1 |
| Hansen, AS | 1 |
| Lambertsen, KL | 1 |
| Kruuse, C | 1 |
| Christensen, CE | 2 |
| Ghanizada, H | 1 |
| Younis, S | 2 |
| Olinger, ACR | 2 |
| de Koning, PJH | 1 |
| Larsson, HBW | 2 |
| Fliedner, FP | 1 |
| Tolnai, D | 1 |
| Birgens, H | 1 |
| Daldrup-Link, H | 1 |
| Kjær, A | 1 |
| Lindberg, U | 1 |
| Hansen, EK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache[NCT03422796] | 30 participants (Actual) | Interventional | 2017-11-01 | Completed | |||
| The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model[NCT02486276] | 30 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers. Development of a Pragmatic Migraine Model[NCT03156920] | 30 participants (Actual) | Interventional | 2017-05-23 | Completed | |||
| Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI[NCT02549898] | 34 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for cilostazol and Abdominal Migraine
| Article | Year |
|---|---|
Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans.
Topics: Calcitonin Gene-Related Peptide; Cilostazol; Cyclic AMP; Humans; Migraine Disorders; Receptors, Calc | 2023 |
Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients.
Topics: Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Subcutaneous | 2020 |
Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol.
Topics: Adult; Cilostazol; Female; Humans; Male; Middle Aged; Migraine Disorders; Phosphodiesterase 3 Inhibi | 2018 |
Cilostazol induced migraine does not respond to sumatriptan in a double blind trial.
Topics: Adult; Cilostazol; Cross-Over Studies; Cyclic AMP; Double-Blind Method; Female; Humans; Male; Middle | 2018 |
Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers.
Topics: Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Headache; Healthy Volunteers; Hu | 2018 |
Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura.
Topics: Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migra | 2018 |
Meningeal contribution to migraine pain: a magnetic resonance angiography study.
Topics: Adolescent; Adult; Carotid Arteries; Cilostazol; Female; Headache; Humans; Magnetic Resonance Angiog | 2019 |
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging.
Topics: Adult; Animals; Brain; Cilostazol; Dextrans; Female; Humans; Inflammation; Macrophages; Magnetic Res | 2019 |
Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers.
Topics: Adolescent; Adult; Cilostazol; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; | 2016 |
3 other studies available for cilostazol and Abdominal Migraine
| Article | Year |
|---|---|
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cilostazol; Cromakalim; Humans; Mice; Mice, Knockout; Migr | 2021 |
Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats.
Topics: Animals; Behavior, Animal; Cilostazol; Disease Models, Animal; Female; Migraine Disorders; Proto-Onc | 2018 |
Cilostazol as a chemically induced preclinical model of migraine.
Topics: Animals; Cilostazol; Female; Headache; Migraine Disorders; Photophobia; Rats; Trigeminal Nuclei | 2018 |